Medtronic Cardiac and Vascular ’s Post

The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/43NEsw2 Risk Info: https://bit.ly/4aKWBwY TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year:¹ https://bit.ly/49SGIU1 Risk Info: https://bit.ly/3UtKYF2 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year¹: https://bit.ly/4eb8a31 Risk Info: https://bit.ly/4aKlCI1 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Did you know? Once impacted by severe #AorticStenosis, women suffer from higher mortality than men, even after matching for age.¹ With the #SMARTtrial, we now know that women with small annuli who are treated with Evolut™ #TAVR experience superior valve performance at 1 year vs. SAPIEN platform.² Explore the evidence: https://bit.ly/43YzufX Risk Info: https://bit.ly/3W19YoE TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1 . Tribouilly C, et al. J Am Heart Assco. 2021;10:e018816. 2. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN™* platform at 1 year.¹ Explore the evidence: https://bit.ly/3QClH9n Risk Info: https://bit.ly/3WyhSWv TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024

The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN™* platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3wymm4S Risk Info: https://bit.ly/4aatMct TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3J8N9HF Risk Info: https://bit.ly/3Jbw1kK TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/4aryVhk Risk Info: https://bit.ly/49AjEJz TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Because women typically have smaller annuli than men, they require a valve that provides the largest area of blood flow to maximize valve performance. Valve choice makes a difference. The Evolut™ #TAVR system has a unique design that enables greater blood flow and improved outcomes compared to SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/442CAja #AorticStenosis #SMARTtrial Risk Info: https://bit.ly/4cSqvB4 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Did you know? Once impacted by severe #AorticStenosis, women suffer from higher mortality than men, even after matching for age.¹ With the #SMARTtrial, we now know that women with small annuli who are treated with EvolutTM #TAVR experience superior valve performance at 1 year vs. SAPIEN™* platform.² Explore the evidence: https://bit.ly/4bAgpnz Risk Info: https://bit.ly/3VfTat3 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1 . Tribouilly C, et al. J Am Heart Assco. 2021;10:e018816. 2. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.